Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma

BACKGROUND: Neuroblastoma (NB) places a substantial health burden on families worldwide. This study aimed to develop an immune checkpoint-based signature (ICS) based on the expression of immune checkpoints to better assess patient survival risk and potentially guide patient selection for immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Liang, Xu, Hui, Li, Shu-Hua, Xu, Shuo-Yu, Chen, Kai, Qin, Liang-Jun, Miao, Lei, Wang, Fang, Deng, Ling, Wang, Feng-Hua, Li, Le, Fu, Sha, Liu, Na, Wang, Ran, Li, Ying-Qing, Wang, Hai-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163522/
https://www.ncbi.nlm.nih.gov/pubmed/37130627
http://dx.doi.org/10.1136/jitc-2022-005980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163522/
https://www.ncbi.nlm.nih.gov/pubmed/37130627
http://dx.doi.org/10.1136/jitc-2022-005980

Ejemplares similares